Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Verve Therapeutics VERV in the last three months. The table below provides a snapshot of their ...

U.S. stock indexes are losing ground on Tuesday, while oil prices rise again.The S&P 500 was down 0.8% in afternoon trading<a ...

Stocks declined Tuesday and oil prices rose as Israel and Iran continued to exchange missile attacks and as hopes for a quick ...

Tokyo’s Nikkei 225 index rose 0.6% after the Bank of Japan opted to keep its key interest rate unchanged. It’s been gradually ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

US stocks are down after Trump had harsh words for Iran, saying he would not target the country's leader "for now." Fed's ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Deal would add a potential treatment for cardiovascular disease to Eli Lilly's portfolio. The food giant says it will remove the dyes from products including Jell-O, Kool-Aid and Crystal Light before ...

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease, with its lead program ...